642 results on '"Zu, Youli"'
Search Results
2. Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
3. Cell-free DNA 5-hydroxymethylcytosine is highly sensitive for MRD assessment in acute myeloid leukemia
4. A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
5. Aptamer-armed nanostructures improve the chemotherapy outcome of triple-negative breast cancer
6. DNA mismatch repair defect and intratumor heterogeneous deficiency differently impact immune responses in diffuse large B-cell lymphoma.
7. RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway
8. Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells
9. MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
10. A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors
11. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
12. Rapid growth of acquired UBA1 mutations predisposes male patients to low-risk MDS
13. Rapid growth of acquired UBA1mutations predisposes male patients to low-risk MDS
14. Implementing flowDensity for Automated Analysis of Bone Marrow Lymphocyte Population
15. MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma
16. G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?
17. Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms
18. Peripheral T cell lymphoma, NOS with aberrant αβ and γδ T cell receptor expression in a post-heart transplant patient
19. Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers
20. Supplementary Figures from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
21. Table S1. LILRB1-4 surface expression in AML patient samples from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
22. Table S2. Ingenuity Pathway Analysis of LILRB3 antibody treated U937 cells from LILRB3 Modulates Acute Myeloid Leukemia Progression and Acts as an Effective Target for CAR T-cell Therapy
23. Updates in Polycythemia Vera
24. Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies
25. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
26. ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions
27. Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL
28. Spin-Valve based magnetoresistive nanoparticle detector for applications in biosensing
29. XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53
30. Recombinant expression, characterization, and quantification in human cancer cell lines of the Anaplastic Large-Cell Lymphoma-characteristic NPM-ALK fusion protein
31. Classification of Acute Myeloid Leukemia by Cell-Free DNA 5-Hydroxymethylcytosine
32. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
33. B7-H4 expression in ovarian serous carcinoma: a study of 306 cases
34. Aptamer technology: a new approach to treat lymphoma?
35. Data from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents
36. Supplementary Tables 1-5 and Supplementary Figures 1-8 from Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents
37. EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential
38. Supplmentary Documents including Methods, Tables, and Legends for Supplementary Figures, and Supplementary Figure S1-S5 from Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
39. Supplementary Figure from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
40. Supplementary Table 1 from Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
41. Supplementary Data from Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma
42. Supplementary Figure 1 from Prevalence and Clinical Implications of Epstein–Barr Virus Infection in De Novo Diffuse Large B-Cell Lymphoma in Western Countries
43. Supplement Figures 1 - 5 and Tables 1 - 6 from Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
44. Data from Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
45. Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
46. Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy
47. Author Correction: ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions
48. Evaluation of NF-κB subunit expression and signaling pathway activation demonstrates that p52 expression confers better outcome in germinal center B-cell-like diffuse large B-cell lymphoma in association with CD30 and BCL2 functions
49. 18. Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
50. Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.